Pasireotide that has high affinity for SSTR1, 2, 3 and 5 has been reported to decrease cortisol levels in patients with Cushing’s disease, although this was associated with hyperglycaemia-related adverse events in approximately 75% of patients (Colao et al. 2012). This evidence concerns the gene SSTR1 and Hyperglycemia.